AllianceBernstein
OMED

AllianceBernstein’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

AllianceBernstein’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,300
Closed -$205K – 3260
2017
Q1 		$205K Hold
22,300
– – ﹤0.01% 2848
2016
Q4 		$172K Hold
22,300
– – ﹤0.01% 2921
2016
Q3 		$255K Buy
22,300
+5,400
+32% +$62.9K ﹤0.01% 2757
2016
Q2 		$208K Buy
+16,900
New +$205K ﹤0.01% 2795
2016
Q1 		– Sell
-11,400
Closed -$257K – 2996
2015
Q4 		$257K Sell
11,400
-1,400
-11% -$28.7K ﹤0.01% 2672
2015
Q3 		$212K Hold
12,800
– – ﹤0.01% 2761
2015
Q2 		$288K Buy
12,800
+3,900
+44% +$96.2K ﹤0.01% 2767
2015
Q1 		$229K Buy
8,900
+3,700
+71% +$93.8K ﹤0.01% 2774
2014
Q4 		$113K Sell
5,200
-1,400
-21% -$28.7K ﹤0.01% 2966
2014
Q3 		$125K Buy
6,600
+100
+2% +$2.01K ﹤0.01% 2909
2014
Q2 		$151K Buy
6,500
+5,027
+341% +$124K ﹤0.01% 2898
2014
Q1 		$50K Buy
1,473
+1,400
+1,918% +$47.2K ﹤0.01% 3117
2013
Q4 		$2K Hold
73
– – ﹤0.01% 3307
2013
Q3 		$1K Buy
+73
New +$1.35K ﹤0.01% 3447

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein's OMED Position: Q2 2017 in Review

AllianceBernstein sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 22,300 shares — an estimated $205K sold.

AllianceBernstein first reported a position in OMED in Q3 2013 and held it in 14 quarters. The position peaked at $288K in Q2 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • AllianceBernstein reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • AllianceBernstein sold 22,300 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $205K.
  • AllianceBernstein first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 14 quarters.
  • AllianceBernstein's OncoMed Pharmaceuticals, Inc. position peaked at $288K in Q2 2015.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on AllianceBernstein's 13F filing for Q2 2017, filed 10 Aug 2017.